Table 1 Demographic, disease, and treatment features of the study population at the start of combination treatment
Variable | Study population (n = 20) |
|---|---|
Age (years) | 61 (50–71) |
Female sex | 14 (70%) |
Caucasian ethnicity | 17 (85%) |
Inflammatory idiopathic myopathy subgroup | |
Anti-synthetase syndrome | 12 (60%) |
Overlap myositis | 3 (15%) |
Dermatomyositis | 2 (10%) |
Polymyositis | 2 (10%) |
Necrotizing myositis | 1 (5%), |
Disease duration (months) | 23 (10–118) |
Concomitant glucocorticoid therapy | |
Prevalence | 17 (85%) |
Median daily dosage (mg) | 8.75 (5-12.5) |
Previous immunosuppressants | |
Methotrexate | 8 (40%) |
Calcineurin inhibitors | 6 (30%) |
Azathioprine | 5 (25%) |
Cyclophosphamide | 4 (20%) |
Intravenous immunoglobulins | 3 (15%) |
Previous or current inflammatory involvement | |
Muscle | 16 (80%) |
Lung | 15 (75%) |
Heart | 7 (35%) |
Joint | 6 (30%) |
Skin | 3 (15%) |